Benjamin F. Edwards & Company, Inc. Tg Therapeutics, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 900 shares of TGTX stock, worth $28,530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
900
Previous 900
-0.0%
Holding current value
$28,530
Previous $14,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding TGTX
# of Institutions
349Shares Held
89.5MCall Options Held
2.35MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA15.4MShares$488 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$361 Million0.0% of portfolio
-
State Street Corp Boston, MA9.09MShares$288 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$114 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA3.21MShares$102 Million0.01% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.61B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...